By proceeding, you agree to our Terms of Use and Privacy Policy.
Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development.
13-16 June 2022
As there is no substitute for in-person collaboration, BIO is back this year offering ample opportunities to connect with peers and those who can help you achieve your business goals. Check out our growing list of the events and receptions that BIO h
Event Ended
USA
Paid
San Diego
19-21 July 2022
Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.
Boston
07-08 August 2023
Great progress has been made in studying cancer immunology and the development of immunotherapies. The complexity of the immune system and the duplicity of cancer, plus the expense of treatments and variable patient responses, make for a perfect data
Cell therapies such as CAR Ts are now a proven treatment approach for hematological cancers, but challenges remain around CAR T’s ability to target solid tumors. Cambridge Healthtech Institute’s Tenth Annual Advances in CAR T Therapy conference bring
Bispecific antibodies are generating increased excitement for their potential to effectively target complex diseases through a dual-engagement approach. There are many new and powerful breakthroughs with bispecific antibodies relating to fine tuning
07-09 August 2023
Over the past 11 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncol
08-09 August 2023
Advances in harnessing the immune system for therapeutic development have resulted in a robust pipeline of immuno-oncology therapies and novel combinations. A successful program requires appropriate models and tools for preclinical evaluation and eff
Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many a